Threshold Pharmaceuticals Inc. (THLD) Price Target Lowered to $0.52 at S&P Equity Research
Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.6775 on Friday. The company has a 50-day moving average of $1.06 and a 200-day moving average of $0.62. The stock has a market capitalization of $48.45 million, a price-to-earnings ratio of 1.1444 and a beta of 3.98. Threshold Pharmaceuticals has a one year low of $0.21 and a one year high of $4.44.
Threshold Pharmaceuticals (NASDAQ:THLD) last issued its earnings results on Monday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.10). On average, equities analysts forecast that Threshold Pharmaceuticals will post ($0.38) EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in THLD. Oxford Asset Management increased its position in Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock worth $129,000 after buying an additional 178,602 shares in the last quarter. Paloma Partners Management Co acquired a new position in Threshold Pharmaceuticals during the second quarter worth about $152,000. Renaissance Technologies LLC increased its position in Threshold Pharmaceuticals by 55.5% in the first quarter. Renaissance Technologies LLC now owns 1,016,764 shares of the biotechnology company’s stock worth $468,000 after buying an additional 363,100 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock worth $1,610,000 after buying an additional 500,000 shares in the last quarter. Finally, Deerfield Management Co. acquired a new position in Threshold Pharmaceuticals during the second quarter worth about $1,641,000. Hedge funds and other institutional investors own 28.22% of the company’s stock.
Threshold Pharmaceuticals Company Profile
Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Stock Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.